SQI Diagnostics reports net loss of $1,563,000 for quarter-ended December 31, 2012

Published on February 15, 2013 at 12:02 AM · No Comments

SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the first quarter-ended December 31, 2012.

Highlights for the quarter-ended December 31, 2012

  • Our sales team completed twelve in person sales meetings which were the result of a significant number of prospecting and qualifying tele-meetings, trade show and scientific conference presentations.
  • On October 14-18, 2012 the Company launched its SQiDlite system at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
  • On November 12-16, 2012 the Company presented at the European Bioanalysis Forum Open Symposium which highlighted our ability to multiplex and automate immunogenicity tests.
  • Verification work advanced on the Ig_PLEX Celiac DGP Panel. The Company has made significant progress on issues encountered in its initial verification testing and now expects validation to commence in the second fiscal quarter of 2013 followed shortly by completion and submission of applications for regulatory approval in both Canada and the United States.
  • SQI was asked to participate in the Emerging Technologies Action Program Committee (ETAPC), an industry working group comprising industry leaders. The Committee focuses on evaluating the potential of emerging technologies for biologics quantification and its current interest is in technologies in multiplexing and automation that result in cost reductions. The Company was and continues to be an active participant in ETAPC.
  • Subsequent to quarter end the Company announced a collaboration with Algorithme Pharma to develop a multiplex proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds. As the first step in marketing the commercial product SQI and Algorithme will present the results of the proof of concept studies at the upcoming 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore 18-20 March, in a presentation titled "A Novel Approach for Multiplexed Detection, Isotyping, and Quantitation of IgG, IgA, and IgM PF4/Heparin Antibodies using SQI Diagnostics' Ig_Plex™ Technology".
  • During the quarter the Company announced that it had established a special committee to review strategic alternatives to maximize growth and shareholder value. At this time the Company's advisers have generated interest from a number of parties that are at various stages of the process. Further information regarding the strategic process can be found in the Company's MD&A available on SEDAR.

"SQI made significant progress in generating customer interest in its Diagnostic Tools and Services offerings during the quarter through a variety of sales and marketing initiatives," said Andrew Morris, CFO of SQI Diagnostics. "We believe that our Algorithme Pharma collaboration and the expected positive outcome of our proof of concept studies will generate additional sales for the Diagnostic Tools and Services business."

Financial Results

For the quarter-ended December 31, 2012, SQI recorded a net loss of $1,563,000 or $0.04 per share, compared to a net loss of $1,650,000 or $0.05 per share for the quarter-ended December 31, 2011.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment